ARTICLE | Clinical News
Contrave naltrexone SR/bupropion SR regulatory update
April 13, 2015 7:00 AM UTC
The European Commission approved Mysimba naltrexone/buproprion as an adjunct to diet and exercise for weight management in adult patients with a BMI of >=30 kg/m 2 or a BMI of >=27 with at least 1 wei...